GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genix Pharmaceuticals Corp (TSXV:GENX) » Definitions » EV-to-EBIT

Genix Pharmaceuticals (TSXV:GENX) EV-to-EBIT : -0.85 (As of May. 10, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Genix Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genix Pharmaceuticals's Enterprise Value is C$3.53 Mil. Genix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-4.16 Mil. Therefore, Genix Pharmaceuticals's EV-to-EBIT for today is -0.85.

The historical rank and industry rank for Genix Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

TSXV:GENX' s EV-to-EBIT Range Over the Past 10 Years
Min: -155.44   Med: -14.74   Max: 862.66
Current: -0.85

During the past 13 years, the highest EV-to-EBIT of Genix Pharmaceuticals was 862.66. The lowest was -155.44. And the median was -14.74.

TSXV:GENX's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.94 vs TSXV:GENX: -0.85

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genix Pharmaceuticals's Enterprise Value for the quarter that ended in Jan. 2024 was C$2.93 Mil. Genix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was C$-4.16 Mil. Genix Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -141.74%.


Genix Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Genix Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genix Pharmaceuticals EV-to-EBIT Chart

Genix Pharmaceuticals Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.05 -12.71 -5.33 -3.79 -0.66

Genix Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.07 -2.88 -4.67 -0.66 -0.71

Competitive Comparison of Genix Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genix Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genix Pharmaceuticals's EV-to-EBIT falls into.



Genix Pharmaceuticals EV-to-EBIT Calculation

Genix Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3.527/-4.16
=-0.85

Genix Pharmaceuticals's current Enterprise Value is C$3.53 Mil.
Genix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genix Pharmaceuticals  (TSXV:GENX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genix Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2024 ) =EBIT / Enterprise Value (Q: Jan. 2024 )
=-4.16/2.934964
=-141.74 %

Genix Pharmaceuticals's Enterprise Value for the quarter that ended in Jan. 2024 was C$2.93 Mil.
Genix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genix Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genix Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Genix Pharmaceuticals (TSXV:GENX) Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company. It operates as a formulator, manufacturer, licensor, and marketer of life sciences related products with a focus on nutraceuticals and pharmaceuticals. Some of its products are Renochlor, Sucanon, and Flu-X. The company primarily operates in Canada.
Executives
Sina Pirooz Director

Genix Pharmaceuticals (TSXV:GENX) Headlines

No Headlines